Canagliflozin and risk of amputation in patients with type 2 diabetes

Abstract

Sodium glucose co-transporter type 2 inhibitors (SGLT2) are a new effective group of oral hypoglygemic drugs for the treatment of diabetes type 2. At the moment there is no unanimous opinion on their safety. The article presents the data on clinical studies CANVAS and CANVAS-R and reports of the international database VigiBase (2015 - 2017) on the risk of amputation in patients with type 2 diabetes undergoing treatment with canagliflozin.

Keywords

• ингибиторы sglt2
• канаглифлозин
• ампутация
• сахарный диабет 2 типа
• inhibitors of sglt2
• canagliflozin
• amputation
• type 2 diabetes